Cyrus Biotechnology logo

Cyrus Biotechnology

cyrusbio.com

Cyrus Biotechnology develops computationally engineered biologics from natural proteins for therapeutic applications, with lead programs targeting severe autoimmune diseases and acute respiratory distress syndrome. The company uses protein design algorithms and laboratory methods to create novel variants and fusion proteins, aiming to provide superior efficacy and address unmet medical needs.

Facts

HQ
Seattle, Washington, US
Sectors
Biotechnology Research
Founded
2014
Type
Corporation Seattle business license
Employees
17
Registered name
Cyrus Biotechnology Inc Seattle business license
Stage
Series B
Members see funding amounts.
.
Founders
David Baker

Is this your organization? Claim it

Seattle’s UW research, Amazon alumni and military adjacency fuel startups building high-stakes, regulation-ready AI for biotech, finance and government

A Seattle high-school intern argues that strict school AI rules illuminated why AI must be disciplined in high-stakes domains, and describes how Seattle's research institutions (notably UW and the David Baker ecosystem), Amazon alumni, and military adjacency produce founders building accountable, regulation-ready AI for biotech, finance, and government.

Nobel Laureate David Baker Drives Protein Design Innovation and Startup Growth at University of Washington

David Baker, Nobel Prize winner and head of the Institute for Protein Design at the University of Washington, is focused on advancing protein design research and entrepreneurship, having helped spawn over 20 startups in Seattle's biotech hub. He plans to continue accelerating scientific innovation in the field, which develops new proteins for therapeutics, vaccines, and materials.

See all 14 news stories about Cyrus Biotechnology.

People

  • Lucas Nivon
    Lucas Nivon Executive Officer, Director, Co-Founder and Chief Executive Officer
  • Yifan Song Director, Co-founder and Chief Technology Officer
  • Erik Procko Executive, Chief Scientific Officer

Online